EMBC · Embecta
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a weekly close below $4.60
Note written ·
Price against the kill line
40.4% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a weekly close below $4.60, on record since 10 November 2026; only a weekly close settles it. The shares are up 26.2% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A weekly close below $4.60, which would erase the recovery since the August 2026 insider purchases; fiscal 2026 adjusted EPS below $1.80 or revenue below $1.015 billion would also break the operating case.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 June 2026, filed 7 August 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 272
- Revenue, change on a year (%)
- −8.1
- Gross margin (%)
- 56.4
- Operating margin (%)
- 17.9
- Free cash flow, four quarters ($M)
- 165
- Net cash, cash less debt ($M)
- −1,240
- Price to earnings (×)
- 4.2
- Enterprise value to sales (×)
- 1.6
All filed numbers
What Embecta reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 272 | −8.1 | 56.4 | 17.9 |
| first filed | 222 | −14.4 | 57.6 | 15.8 |
| first filed | 261 | −0.3 | 61.9 | 31.9 |
| first filed | 264 | −7.7 | 60.0 | 21.4 |
| first filed | 296 | +8.4 | 66.7 | 31.8 |
| first filed | 259 | −9.8 | 63.4 | 24.3 |
| Pre-tax income ($M) | 27.6 |
| Net income ($M) four quarters: 87.5 | 21.1 |
| Diluted shares, change on a year (%) against the quarter to 30 June 2025 | 0.0 |
| Operating cash flow ($M) | 174 |
| Capital spending ($M) | 9.5 |
| Free cash flow ($M) | 165 |
| Cash and short-term investments ($M) | 215 |
| Debt ($M) non-current long-term debt plus current maturities | 1,455 |
| Net cash, cash less debt ($M) | −1,240 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 182 |
| Inventory ($M) | 214 |
| Shareholders' equity ($M) | −613 |
| Market value ($M) | 366 |
| Enterprise value, market value plus net debt ($M) | 1,606 |
| Enterprise value to sales (×) | 1.6 |
| Enterprise value to operating income (×) | 7.2 |
| Price to earnings (×) | 4.2 |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | 45.0 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 10.4% of shares outstanding sold short, 6.2 days of average trading to cover, +0.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $37K |
| 12 monthsfrom | $558K | $37K |
The thesis
Embecta Corp. shares are modestly favored to beat the S&P 500 over the next three months. The case is that higher margins, cash generation and debt repayment will outweigh shrinking U.S. pen-needle sales. The fiscal fourth-quarter and full-year 2026 report settles it. On 10 November 2026, Embecta announced that the report and a conference call with preliminary fiscal 2027 guidance would come on 24 November 2026.
The rating is Medium because the 7 August 2026 guidance raise and the insider buying in August 2026 still stand against a balance sheet that remains heavy. The price already reflects a good report. The shares closed at $6.53 on 11 November 2026, above every published analyst target; StockAnalysis showed a $5.00 high on 9 November 2026.
The Pfizer collaboration was announced on 5 November 2026, per fiscal.ai's company news feed. As of 12 November 2026 it had no published financial terms, products or geography. Its financial weight stays unknown until Embecta discusses it, most likely on the 24 November 2026 call.
Bullish and bearish views on Embecta Corp.
The bull case on Embecta Corp. (EMBC), in brief: earnings guidance moved higher in August. The bear case: U.S. sales kept contracting.
Bull case
- Earnings guidance moved higher in August. On 7 August 2026, Embecta raised fiscal 2026 adjusted earnings per share (EPS) guidance to $1.80–$1.90 from $1.55–$1.75. It raised adjusted operating margin guidance to 23.50%–24.00% from 22.25%–23.25% and reaffirmed revenue of $1.015–$1.035 billion.
- Consensus sits inside the raised range. S&P Global's consensus, shown by StockAnalysis on 9 November 2026, puts fiscal 2026 adjusted EPS at $1.84 on revenue of about $1.02 billion. A result at that level on 24 November 2026 would confirm the August guidance.
- Pfizer joins the partner list. The 5 November 2026 announcement names Pfizer as a metabolic health and diabetes partner. In its fiscal Q2 2026 release, Embecta said about 40% of the partners identified in its generic GLP-1 (the drug class behind weight-loss injections) pipeline were in negotiations or under executed agreements.
- Cash is paying down debt. Embecta reported non-GAAP free cash flow of $40.7 million in the quarter ended 30 June 2026. It repaid about $53 million of debt in that quarter, most of it on the revolving credit line.
- Drug delivery broadens the product line. Embecta closed its acquisition of UK device maker Owen Mumford on 15 May 2026, for £100 million in cash plus up to £50 million tied to sales of the Aidaptus auto-injector, per trade press reports. Owen Mumford had about £69.4 million of net revenue in its fiscal year ended 30 September 2025.
- Management bought shares as a group. SEC Form 4 filings dated 13 August 2026 show Chief Executive Devdatt Kurdikar bought 30,000 shares at about $4.70 and director Robert Hombach bought 45,000 at $4.97. The chief financial officer and another officer bought 20,000 each.
Bear case
- U.S. sales kept contracting. Fiscal Q3 U.S. revenue fell 24.6% year over year to $120.8 million, per the 7 August 2026 release. Total revenue fell 8.1% to $271.7 million.
- Part of the international growth was bought. International revenue rose 11.5% to $150.9 million in the June 2026 quarter, the first quarter to include Owen Mumford after its 15 May 2026 closing. The underlying pen-needle trend outside the U.S. is likely weaker than the headline figure.
- Earnings halved from a year ago. Fiscal Q3 adjusted EPS was $0.56 against $1.12 a year earlier. Free cash flow of $40.7 million compared with $80.8 million a year earlier.
- Debt is still heavy. Debt principal was $1.469 billion at 30 June 2026, including $129.9 million on the revolver, which funded the Owen Mumford cash payment. Cash and restricted cash were $218.2 million, and management cited net leverage of roughly 3.7 times on the 7 August 2026 call.
- Analysts value the shares lower. StockAnalysis showed a four-analyst consensus target of $4.00 on 9 November 2026, with a $5.00 high and a $3.00 low. Ratings are three Hold and one Sell, and S&P Global's fiscal 2027 adjusted EPS consensus of $1.76 is below the $1.84 expected for fiscal 2026.
- One director sold into the rally. A Form 4 filed 8 September 2026 shows director Milton Mayo Morris sold 6,293 shares at $5.88 on 4 September 2026 in the open market.
- The dividend was cut and litigation is pending. The quarterly dividend fell to $0.01 from $0.15 with the fiscal Q2 2026 report. A securities class action covers purchases from 25 November 2025 to 4 May 2026.
Price setup
The shares closed at $6.53 on 11 November 2026, up 28.0% over three months on adjusted daily closes. The close sits above both the 50-day moving average of $5.94 and the 200-day moving average of $6.19, as of 11 November 2026. The shares closed at $6.52 on 4 November 2026, slipped to $6.19 on 6 November 2026 and recovered over the next three sessions.
The price range the case turns on runs from the 52-week closing low of $2.90 on 19 May 2026 to the roughly $4.70 to $4.97 range where the chief executive and a director bought in August 2026. Above the market, the 52-week intraday high is $14.91 from 12 November 2025, and the last close is 56.2% below it.
Short interest was 5.55 million shares, or 9.92% of the float, as of 15 September 2026, according to a MarketBeat report published 24 September 2026. With the shares already above the highest analyst target, the 24 November 2026 report and fiscal 2027 outlook are the next company events that can reset the price.
Catalysts ahead
- 24 November 2026: Fiscal Q4 and full-year 2026 earnings report and conference call with preliminary fiscal 2027 guidance. Tests U.S. sales, free cash flow and debt reduction against $1.80–$1.90 adjusted EPS guidance, sets the first fiscal 2027 outlook against a $1.76 consensus, and may give the first financial detail on the Pfizer collaboration.
What would change the view
A weekly close below $4.60, which would erase the recovery since the August 2026 insider purchases; fiscal 2026 adjusted EPS below $1.80 or revenue below $1.015 billion would also break the operating case.
The risks this note tracks, each with what would confirm it:
- U.S. pen-needle sales continue to contract despite the international offset. Confirmed by: fiscal Q4 U.S. revenue falling faster year over year than the 24.6% decline reported for fiscal Q3 2026.
- Debt burden rises as cash generation slows after the revolver-funded Owen Mumford purchase. Confirmed by: the fiscal 2026 filing showing net leverage above the roughly 3.7 times cited on the 7 August 2026 call.
- The first fiscal 2027 outlook shows earnings declining more than analysts expect. Confirmed by: initial fiscal 2027 adjusted EPS guidance below the $1.76 S&P Global consensus at the 24 November 2026 report.
- The Pfizer collaboration proves commercially small. Confirmed by: the fiscal 2027 outlook and the 24 November 2026 call attributing no measurable revenue to the agreement.
- The share price stays ahead of analyst valuations, which all sit below it. Confirmed by: target updates after the 24 November 2026 report that leave the $5.00 high target unchanged or lower, or a new downgrade.
- Litigation costs or a settlement weigh on cash available for debt repayment. Confirmed by: a disclosed settlement, reserve or legal expense in the fiscal 2026 annual report tied to the pending securities class action.
- The autumn gains reverse before the report without new company disclosure. Confirmed by: a close below the 50-day moving average, $5.94 as of 11 November 2026, before 24 November 2026 with no new company news.
What it trades with
Embecta trades mainly on its own results and balance sheet. Broad medtech indices are a weaker guide. Its partnership program ties the case to global adoption of injectable GLP-1 drugs, especially generic versions outside the U.S., and Pfizer is the newest named partner. International revenue exceeded U.S. revenue in fiscal Q3 2026, and Owen Mumford reports in sterling, so a stronger dollar reduces reported sales. With $1.469 billion of debt principal at 30 June 2026, the equity is sensitive to credit conditions and to interest costs on the revolving credit line.
The evidence, claim by claim (8)
- Fiscal 2026 adjusted EPS guidance rose to $1.80–$1.90 from $1.55–$1.75; revenue guidance of $1.015–$1.035 billion was reaffirmed. Embecta fiscal Q3 2026 earnings release, SEC Exhibit 99.1 · as of
- Fiscal Q3 2026 adjusted EPS was $0.56 versus $1.12 a year earlier on revenue of $271.7 million, down 8.1%; U.S. revenue fell 24.6% to $120.8 million and international revenue rose 11.5% to $150.9 million. Embecta fiscal Q3 2026 earnings release, SEC Exhibit 99.1 · as of
- Fiscal Q3 2026 non-GAAP free cash flow was $40.7 million versus $80.8 million a year earlier, with about $53 million of debt repaid. Embecta fiscal Q3 2026 earnings release, SEC Exhibit 99.1 · as of
- Debt principal was $1.469 billion, including $129.9 million on the revolver; cash plus restricted cash was $218.2 million. Embecta fiscal Q3 2026 earnings release, SEC Exhibit 99.1 · as of
- Embecta closed the Owen Mumford acquisition: £100 million cash at closing funded from the revolver, plus up to £50 million contingent on Aidaptus sales over three years; target revenue about £69.4 million in fiscal 2025. Drug Delivery Business News and Yahoo Finance reports on the closing · as of
- Chief Executive Devdatt Kurdikar bought 30,000 shares at about $4.70; director Robert Hombach bought 45,000 at $4.97; the CFO and another officer bought 20,000 each. SEC Form 4 filings dated 13 August 2026 · as of
- Director Milton Mayo Morris sold 6,293 shares in the open market at $5.88 on 4 September 2026. SEC Form 4 filed 8 September 2026 · as of
- Four-analyst consensus target is $4.00 (high $5.00, low $3.00), three Hold and one Sell; consensus adjusted EPS is $1.84 for fiscal 2026 and $1.76 for fiscal 2027. S&P Global Market Intelligence via StockAnalysis forecast page · as of
Sources
- SEC EDGAR
- Embecta Announces Q4 2026 Financial Results Call · biopharmawatch.com
- Stock Analysis
- Embecta completes Owen Mumford acquisition · drugdeliverybusiness.com
- Embecta acquires Owen Mumford for $172.6m · finance.yahoo.com
- SEC EDGAR
Related · shared themes
AZTA
Azenta
Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic…
AVTR
Avantor
Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins…
CRL
Charles River Laboratories International
Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised…
ENOV
Enovis
Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200…
See also · stocks to watch